These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4545519)

  • 1. T lymphocyte requirement for MSV tumour prevention or regression.
    Collavo D; Colombatti A; Chieco-Bianchi L
    Nature; 1974 May; 249(453):169-70. PubMed ID: 4545519
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed tumour appearance and absence of regression in nude mice infected with murine sarcoma virus.
    Stutman O
    Nature; 1975 Jan; 253(5487):142-4. PubMed ID: 1110765
    [No Abstract]   [Full Text] [Related]  

  • 3. Age-dependent regression of M-MSV tumors in CBA/H mice: requirement for a macrophage-adherent cell population.
    Stutman O
    Adv Exp Med Biol; 1976; 73 Pt B():371-8. PubMed ID: 998400
    [No Abstract]   [Full Text] [Related]  

  • 4. The lymphocyte response to a primary viral neoplasm (MSV) through its entire course in BALB-c mice.
    Lamon EW; Skurzak HM; Klein E
    Int J Cancer; 1972 Nov; 10(3):581-8. PubMed ID: 4128689
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor induction by murine sarcoma virus in AKR and C58 mice. Reduction of tumor regression associated with appearance of Gross leukemia virus pseudotypes.
    Chieco-Bianchi L; Colombatti A; Collavo D; Sendo F; Aoki T; Fischinger PJ
    J Exp Med; 1974 Nov; 140(5):1162-79. PubMed ID: 4608945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some characteristics of the antibody-induced cell-mediated cytotoxicity against leukemia cells.
    Britton S; Forman J
    Transplantation; 1974 Feb; 17(2):180-7. PubMed ID: 4590289
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies on the effect of a thymic humoral factor on differentiation of thymus-derived lymphocytes.
    Lonai P; Mogilner B; Rotter V; Trainin N
    Eur J Immunol; 1973 Jan; 3(1):21-6. PubMed ID: 4146225
    [No Abstract]   [Full Text] [Related]  

  • 8. The immune response to primary Moloney sarcoma virus tumors in BALB-c mice: cellular and humoral activity of long-term regressors.
    Lamon EW; Anderson B; Wigzell H; Fenyö EM; Klein E
    Int J Cancer; 1974 Jan; 13(1):91-104. PubMed ID: 4594340
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of Toxoplasma on manifestations of Moloney virus infections.
    McLeod R; Estes RG; Cohen H
    Trans R Soc Trop Med Hyg; 1985; 79(6):781-7. PubMed ID: 2938310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressing Moloney sarcoma virus (M-MSV) induced tumors: effect of host's immunomanipulation.
    Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
    Cell Mol Biol Incl Cyto Enzymol; 1980; 26(2):155-8. PubMed ID: 6970620
    [No Abstract]   [Full Text] [Related]  

  • 11. Decrease of cytotoxic immune lymphoid cells following regression of virus-induced sarcomas in mice.
    Levy JP; Lechlerc JC; Gomard E; Pavie J; Kourilsky F
    Bibl Haematol; 1973; 39():689-97. PubMed ID: 4798253
    [No Abstract]   [Full Text] [Related]  

  • 12. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D; Ronchese F; Zanovello P; Biasi G; Chieco-Bianchi L
    J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction and regression of primary moloney sarcoma virus-induced tumors in mice.
    Fefer A; McCoy JL; Glynn JP
    Cancer Res; 1967 Sep; 27(9):1626-31. PubMed ID: 4860892
    [No Abstract]   [Full Text] [Related]  

  • 14. Blocking of syngeneic effector T cells by soluble tumour antigens.
    Plata F; Levy JP
    Nature; 1974 May; 249(454):271-4. PubMed ID: 4545403
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro cytotoxicity studies of murine sarcoma virus-induced immunity in mice.
    Lavrin DH; Herberman RB; Nunn M; Soares N
    J Natl Cancer Inst; 1973 Nov; 51(5):1497-508. PubMed ID: 4762933
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune reactivity in the Moloney strain of murine sarcoma virus oncogenesis: requirement of thymus-derived lymphocytes for in vivo protection.
    Collavo D; Colombatti A; Biasi G; Chieco-Bianchi L; Davies AJ
    J Natl Cancer Inst; 1976 Mar; 56(3):603-8. PubMed ID: 176399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice.
    Fefer A; McCoy JL; Perk K; Glynn JP
    Cancer Res; 1968 Aug; 28(8):1577-85. PubMed ID: 4876979
    [No Abstract]   [Full Text] [Related]  

  • 18. Senescent loss of resistance to murine sarcoma virus (Moloney) in the mouse.
    Pazmiño NH; Yuhas JM
    Cancer Res; 1973 Nov; 33(11):2668-72. PubMed ID: 4748428
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancement of Moloney sarcoma virus-induced tumor growth by concanavalin A.
    Davis S; Redmon LW; Pearson GR
    Immunol Commun; 1975; 4(1):29-37. PubMed ID: 1090515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of M-MuSV tumour regression associated with T lymphocyte tolerance.
    Chieco-Bianchi L; Collavo D; Zanovell P; De Rossi A; Davies AJ
    Nature; 1980 Jun; 285(5767):667-8. PubMed ID: 6248790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.